Topic: How To Invest

Power Growth Investor Hotline – Friday, October 25, 2024

Article Excerpt

BOSTON SCIENTIFIC CORP., $84.73, is a buy. The company (symbol BSX on New York) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty (blood vessel repair), blood clot filtration, cardiac rhythm management, catheter-aided ultrasound imaging, and many other surgical procedures. It generates 60% of its sales in the U.S. and 40% internationally. In the three months ended September 30, 2024, Boston Scientific’s revenue rose 19.3%, to $4.21 billion from $3.53 billion a year earlier. Excluding one-time items, the company earned $939.0 million, or $0.63 a share. That was up 27.9% from $734.0 million, or $0.50. Boston Scientific’s outlook is positive. In the past few months, it has gained regulatory approvals for several new products across all business categories. Ongoing clinical trials and an active development pipeline should generate further growth. Boston Scientific is a buy. Boston Scientific recent coverage: November 2024 Issue Hotline for October 4, 2024 THERMO FISHER SCIENTIFIC INC., $554.38, is a buy. The company…